Intrapleural use of tissue plasminogen activator and DNase in pleural infection

New England Journal of Medicine

Volumn 365, Issue 6, 2011, Pages 518-526

  Rahman, Najib M ^a,b   Maskell, Nicholas A ^d   West, Alex ^e   Teoh, Richard ^f   Arnold, Anthony ^f   Mackinlay, Carolyn ^g   Peckham, Daniel ^h   Davies, Chris W H ⁱ   Ali, Nabeel ^j   Kinnear, William ^k   Bentley, Andrew ^l   Kahan, Brennan C ^m   Wrightson, John M ^a   Davies, Helen E ^a   Hooper, Clare E ^d   Lee, Y C Gary ⁿ   Hedley, Emma L ^a   Crosthwaite, Nicky ^a   Choo, Louise ^m   Helm, Emma J ^c   Gleeson, Fergus V ^b,c   Nunn, Andrew J ^m   Davies, Robert J O ^a,b   more..

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Oxford Radcliffe National Health Service Trust   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e MEDWAY MARITIME HOSPITAL   (United Kingdom)

^f CASTLE HILL HOSPITAL   (United Kingdom)

^g GREAT WESTERN HOSPITAL   (United Kingdom)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^j KING S MILL HOSPITAL   (United Kingdom)

^k QUEEN S MEDICAL CENTRE   (United Kingdom)

^l WYTHENSHAWE HOSPITAL   (United Kingdom)

^m MEDICAL RESEARCH COUNCIL   (United Kingdom)

ⁿ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DORNASE ALFA; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; COMPLICATION; CONFUSION; CONTROLLED STUDY; DRUG ERUPTION; DRUG RESPONSE; ERYTHEMA; FACTORIAL ANALYSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; INTRAPLEURAL BLEEDING; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PATIENT REFERRAL; PLEURA EFFUSION; PLEURISY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX DRAINAGE; THORAX PAIN; THORAX RADIOGRAPHY;

EID: 80051618075     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1012740     Document Type: Article

References (54)

1. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980;69:507-12. (Pubitemid 10018705)
2. Desrumaux A, François P, Pascal C, etal. Epidemiology and clinical characteristics of childhood parapneumonic empyemas. Arch Pediatr 2007;14:1298-303. (In French.) (Pubitemid 350052537)
3. Roxburgh CS, Youngson GG. Childhood empyema in North-East Scotland over the past 15 years. Scott Med J 2007;52:25-7.
4. Muñoz-Almagro C, Jordan I, Gene A,Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008;46:174-82. (Pubitemid 351269154)
5. Farjah F, Symons RG, Krishnadasan B, Wood DE, Flum DR. Management of pleural space infections: a population-based analysis. J Thorac Cardiovasc Surg 2007;133:346-51.
6. Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: an increasing concern in Canada. Can Respir J 2008;15:85-9. (Pubitemid 351676396)
7. Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. The clinical course and management of thoracic empyema. QJM 1996;89:285-9. (Pubitemid 26107744)
8. Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999;160:1682-7.
9. Maskell NA, Davies CWH, Nunn AJ, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74. [Erratum, N Engl J Med 2005;352:2146.] (Pubitemid 40300295)
10. Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 2006;174:221-7. (Pubitemid 44015396)
11. Netten A, Dennett J, Knight J. Unit costs of health and social care. Canterbury, United Kingdom: Personal Social Services Research Unit, University of Kent, 1999.
12. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997;52:416-21.
13. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema: a randomized, double-blind study. Am J Respir Crit Care Med 1999;159:37-42. (Pubitemid 29036500)
14. Tuncozgur B, Ustunsoy H, Sivrikoz MC, et al. Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial. Int J Clin Pract 2001;55:658-60. (Pubitemid 34023826)
15. Talib SH, Verma GR, Arshad M, Tayade BO, Rafeeque A. Utility of intrapleural streptokinase in management of chronic empyemas. J Assoc Physicians India 2003;51:464-8. (Pubitemid 41315526)
16. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004;170:49-53. (Pubitemid 38997750)
17. Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Lioulias A. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema: a prospective study. Eur J Cardiothorac Surg 2005;28:599-603. (Pubitemid 41345251)
18. Tokuda Y, Matsushima D, Stein GH, Miyagi S. Intrapleural fibrinolytic agents for empyema and complicated parapneumonic effusions: a meta-analysis. Chest 2006;129:783-90.
19. Heffner JE. Multicenter trials of treatment for empyema - after all these years. N Engl J Med 2005;352:926-8. (Pubitemid 40300302)
20. Walker CA, Shirk MB, Tschampel MM, Visconti JA. Intrapleural alteplase in a patient with complicated pleural effusion. Ann Pharmacother 2003;37:376-9. (Pubitemid 36249637)
21. Skeete DA, Rutherford EJ, Schlidt SA, Abrams JE, Parker LA, Rich PB. Intrapleural tissue plasminogen activator for complicated pleural effusions. J Trauma 2004;57:1178-83. (Pubitemid 40053810)
22. Feola GP, Shaw LC, Coburn L. Management of complicated parapneumonic effusions in children. Tech Vasc Interv Radiol 2003;6:197-204. (Pubitemid 38177126)
23. Bishop NB, Pon S, Ushay HM, Greenwald BM. Alteplase in the treatment of complicated parapneumonic effusion: a case report. Pediatrics 2003;111(2):E188-E190.
24. Wells RG, Havens PL. Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology 2003;228:370-8. (Pubitemid 36910074)
25. Weinstein M, Restrepo R, Chait PG, Connolly B, Temple M, Macarthur C. Effectiveness and safety of tissue plasminogen activator in the management of complicated parapneumonic effusions. Pediatrics 2004;113(3):e182-e185.
26. Ray TL, Berkenbosch JW, Russo P, Tobias JD. Tissue plasminogen activator as an adjuvant therapy for pleural empyema in pediatric patients. J Intensive Care Med 2004;19:44-50. (Pubitemid 44544713)
27. Gates RL, Hogan M, Weinstein S, Arca MJ. Drainage, fibrinolytics, or surgery: a comparison of treatment options in pediatric empyema. J Pediatr Surg 2004;39:1638-42. (Pubitemid 39487990)
28. Hall-Stoodley L, Nistico L, Sambanthamoorthy K, et al. Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. BMC Microbiol 2008;8:173.
29. Thomas VC, Thurlow LR, Boyle D, Hancock LE. Regulation of autolysis-dependent extracellular DNA release by Enterococcus faecalis extracellular proteases influences biofilm development. J Bacteriol 2008;190:5690-8.
30. Izano EA, Amarante MA, Kher WB, Kaplan JB. Differential roles of poly-N-acetylglucosamine surface polysaccharide and extracellular DNA in Staphylococcus aureus and Staphylococcus epidermidis biofilms. Appl Environ Microbiol 2008;74:470-6.
31. Eckhart L, Fischer H, Barken KB, Tolker-Nielsen T, Tschachler E. DNase1L2 suppresses biofilm formation by Pseudomonas aeruginosa and Staphylococcus aureus. Br J Dermatol 2007;156:1342-5. (Pubitemid 47029823)
32. Nemoto K, Hirota K, Murakami K, et al. Effect of Varidase (streptodornase) on biofilm formed by Pseudomonas aeruginosa. Chemotherapy 2003;49:121-5. (Pubitemid 36736932)
33. Light RW, Nguyen T, Mulligan ME, Sasse SA. The in vitro efficacy of Varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung 2000;178:13-8. (Pubitemid 30111713)
34. Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest 2000;117:1728-33. (Pubitemid 30413370)
35. Zhu Z, Hawthorne ML, Guo Y, et al. Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model. Chest 2006;129:1577-83. (Pubitemid 43894989)
36. Simpson G, Roomes D, Reeves B. Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 2003;58:365-6. (Pubitemid 36411427)
37. Fujiwara K, Yasumitsu T, Nakagawa K, Shiono S, Fukuhara K. Intrapleural streptokinase-streptodornase in the treatment of empyema and hemothorax. Kyobu Geka 2002;55:1115-9. (In Japanese.)
38. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
39. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol 2003;3:26.
40. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-30.
41. Hagino A, Hamada C, Yoshimura I, Ohashi Y, Sakamoto J, Nakazato H. Statistical comparison of random allocation methods in cancer clinical trials. Control Clin Trials 2004;25:572-84. (Pubitemid 39592862)
42. Rovers MM, Straatman H, Zielhuis GA. Comparison of balanced and random allocation in clinical trials: a simulation study. Eur J Epidemiol 2000;16:1123-9. (Pubitemid 32645836)
43. Forsthye A. Validity and power of tests when groups have been balanced for prognostic factors. Comput Stat Data Anal 1987;5:193-200.
44. A trial of intrapleural streptokinase. N Engl J Med 2005;352:2243-5.
45. Diacon AH, Koegelenberg CFN, Bolliger CT. A trial of intrapleural streptokinase. N Engl J Med 2005;352:2243.
46. Bouros D. A trial of intrapleural streptokinase. N Engl J Med 2005;352:2244.
47. Keenan SP. Streptokinase did not reduce mortality or need for surgical drainage in pleural infection. ACP J Club 2005;143:40.
48. Rosa UW. A trial of intrapleural streptokinase. N Engl J Med 2005;352:2244.
49. Idell S, Zwieb C, Kumar A, Koenig KB, Johnson AR. Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 1992;7:414-26.
50. Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 1997;10:2411-8. (Pubitemid 27479569)
51. Florova G, Komissarov A, Idell S. DNA dramatically potentiates activation of plasminogen by tissue type plasminogen activator. Am J Respir Crit Care Med 2010;181:A6824. abstract.
52. Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 2009;64:317-25.
53. Poulsen J, Kristensen VN, Brygger HE, Delikaris P. Treatment of infected surgical wounds with Varidase. Acta Chir Scand 1983;149:245-8.
54. Suomalainen O. Evaluation of two enzyme preparations - Trypure and Varidase in traumatic ulcers. Ann Chir Gynaecol 1983;72:62-5. (Pubitemid 13067234)